Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Total Non-Current Liabilities (2018 - 2025)

BioNexus Gene Lab's Total Non-Current Liabilities history spans 8 years, with the latest figure at $126943.0 for Q3 2025.

  • For Q3 2025, Total Non-Current Liabilities fell 33.89% year-over-year to $126943.0; the TTM value through Sep 2025 reached $126943.0, down 33.89%, while the annual FY2024 figure was $159741.0, 43.89% up from the prior year.
  • Total Non-Current Liabilities for Q3 2025 was $126943.0 at BioNexus Gene Lab, down from $141347.0 in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $194615.0 in Q2 2024 and bottomed at $39659.0 in Q3 2022.
  • The 5-year median for Total Non-Current Liabilities is $71072.0 (2022), against an average of $99753.5.
  • The largest annual shift saw Total Non-Current Liabilities skyrocketed 237.24% in 2023 before it tumbled 33.89% in 2025.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $65856.0 in 2021, then grew by 7.92% to $71072.0 in 2022, then surged by 56.2% to $111018.0 in 2023, then surged by 43.89% to $159741.0 in 2024, then decreased by 20.53% to $126943.0 in 2025.
  • Per Business Quant, the three most recent readings for BGLC's Total Non-Current Liabilities are $126943.0 (Q3 2025), $141347.0 (Q2 2025), and $147940.0 (Q1 2025).